Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sentinox
- Development stage
- Unknown
- Lead developer
- APR Applied Pharma Research
- Modality
- Small Molecules
- Administration
- Intranasal
01
Overview
Sentinox is an acid-oxidizing solution (AOS) containing 0.005% (50 ppm) hypochlorous acid (HOCl) in a liquid carrier, produced via the proprietary Tehclo electrolysis technology. Developed by Relief Therapeutics and its subsidiary Applied Pharma Research (APR), it is administered as an intranasal spray. Sentinox is designed to reduce the viral load of SARS-CoV-2 and other pathogens in the nasal cavity through irrigation, cleansing, and moistening. It is certified as a Class III Medical Device in Europe. While a clinical trial (NCT04909996) for COVID-19 did not meet its primary endpoint due to sample size limitations and baseline variability, the product is intended to lower the risk of infections by reducing microbial load.
- Brand names
- Sentinox
- Other names
- Acid-oxidizing solutionAOS
Beyond the preview
Go deeper on Sentinox.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sentinox.